Related Experiment Video
Updated: Apr 15, 2026
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Molecular Pathways: Targeting Cellular Energy Metabolism in Cancer via Inhibition of SLC2A1 and LDHA
Aik T Ooi1, Brigitte N Gomperts2
1Mattel Children's Hospital UCLA, Department of Pediatrics, UCLA, Los Angeles, California.
Abstract:
Reprogramming of cellular energy metabolism is widely accepted to be one of the main hallmarks of cancer. The aberrant expression pattern of key regulators in the glycolysis pathway in cancer cells corroborates with the hypothesis that most cancer cells utilize aerobic glycolysis as their main ATP production method instead of mitochondrial oxidative phosphorylation. Overexpression of SLC2A1 and LDHA, both important regulators of the glycolysis pathway, was detected in the premalignant lesions and tumors of lung cancer patients, suggesting the involvement of these proteins in early carcinogenesis and tumor progression in cancer. Preclinical studies demonstrated that inhibiting SLC2A1 or LDHA led to diminished tumor growth in vitro and in vivo. SLC2A1 and LDHA inhibitors, when administered in combination with other chemotherapeutic agents, showed synergistic antitumor effects by resensitizing chemoresistant cancer cells to the chemotherapies. These results indicate that disrupting SLC2A1, LDHA, or other regulators in cancer cell energetics is a very promising approach for new targeted therapies.
Insights
Cancer cells reprogram energy metabolism using aerobic glycolysis. Inhibiting key glycolysis regulators like SLC2A1 and LDHA shows promise for targeted cancer therapies and overcoming chemoresistance.
Area of Science:
- Oncology
- Cellular Metabolism
Background:
- Cancer cells exhibit altered energy metabolism, primarily aerobic glycolysis, for ATP production.
- Key glycolysis regulators, SLC2A1 and LDHA, are overexpressed in lung cancer, indicating their role in carcinogenesis.
Purpose of the Study:
- To investigate the role of SLC2A1 and LDHA in cancer cell energetics.
- To evaluate the therapeutic potential of inhibiting these glycolysis regulators.
Main Methods:
- Analysis of SLC2A1 and LDHA expression in lung cancer tissues.
- Preclinical studies involving inhibition of SLC2A1 and LDHA in vitro and in vivo.
- Assessment of combination therapy with SLC2A1/LDHA inhibitors and chemotherapeutics.
Main Results:
- Overexpression of SLC2A1 and LDHA was observed in lung cancer premalignant lesions and tumors.
- Inhibition of SLC2A1 or LDHA significantly reduced tumor growth.
- Combined inhibition with chemotherapy demonstrated synergistic antitumor effects and resensitized resistant cells.
Conclusions:
- SLC2A1 and LDHA are crucial for cancer cell energy metabolism and progression.
- Targeting SLC2A1 and LDHA represents a promising strategy for novel cancer therapies.
- Disrupting cancer cell energetics offers a potential approach to overcome chemoresistance.
Related Concept Videos
01:46Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:34Inhibition of Cdk Activity
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:32Secondary Active Transport